ROCKET PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.72 USD | -2.61% |
|
-3.20% | -24.19% |
| May. 10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
| May. 10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
Presenter SpeechColin Bristow (Analysts)Well, good morning, everyone, and welcome to day 2 of ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
22.72
USD
Average target price
50.08
USD
Spread / Average Target
+120.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.19% | 2.06B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Transcript : Rocket Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-24-2022 07